A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
Completed · Phase 2, Phase 3 · NCT04796896
Conditions: SARS-CoV-2
At a glance
- Research payments reported, 2025
- $333,228
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 11,942
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1273 (biological), Placebo (biological), mRNA-1273.214 (biological)
- Dates
- Started 2021-03-15; completion 2024-03-15
- Results posted
- Yes
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an optional booster dose (BD) (in Parts 1 and 2).
From ClinicalTrials.gov, last updated 2025-06-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $333,228 in research payments for this study in 2025 (20 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Khozema A. Palanpurwala, MD Pediatrics · Houston, TX
- Richard L. Bennett JR., MD Pediatrics · Richmond, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dynamed Clinical Research LP $294,651
- Clinical Research PArtners LLC $38,577
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.